Nikolai Petrovsky | Chairman
Vaxine Pty.

Nikolai is Professor of Immunology and Infectious Disease at the Australian Respiratory and Sleep Medicine Institute in Adelaide and is a leading physician-scientist in the area of vaccine and adjuvant development. He is Research Director for Vaxine, an Australian biotechnology company. His SpikoGen® protein-based COVID-19 vaccine was licensed in the Middle East where 8 million doses were used. He developed CpG55.2, a toll-like receptor 9 agonist that is the first licensed human drug product to be discovered by artificial intelligence. He has authored over 325 peer-reviewed research papers attracting over 33,957 citations, and has an h-index of 73.